Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the TNL Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

COVID-19 vaccines generated trillions in benefits, far exceeding their estimated costs (opens in a new tab)

medicalxpress.com · 2026-11-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 2 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of four check out. One claim the study doesn't address.

  • 2 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3

The source study

Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation

PLOS Medicine · 2026
Open source record (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedThe researchers found significant disparities in return on investment across countries, with high-income countries benefiting more than low- and middle-income countries because of early access, higher uptake, faster rollouts and older populations at risk for severe outcomes.View evidenceHide evidence

Why this verdict

The abstract-level profile supports distributional differences by income group and reports that high-income countries had the greatest health benefits per person vaccinated, while low-income countries had the greatest nonhealth benefits per person vaccinated when scaled to GDP per capita. The story’s broader claim that high-income countries benefited more overall than low- and middle-income countries, and its stated reasons such as early access, higher uptake, faster rollouts, and older at-risk populations, go beyond what is supported in the supplied abstract profile and flatten the paper’s metric-specific nuance.

1

Study evidence

High-income countries saw the greatest health benefits per-person vaccinated, and low-income countries gained the greatest nonhealth benefits per-person vaccinated, when expressed as a proportion of gross domestic product per capita.

“High-income countries saw the greatest health benefits per-person vaccinated, and low-income countries gained the greatest nonhealth benefits per-person vaccinated, when expressed as a proportion of gross domestic product per capita.”
Claim 2 of 4Not coveredThe authors say the study covered the first year of vaccine availability, from Dec. 8, 2020 to Dec. 8, 2021, and used data from 173 countries.View evidenceHide evidence

As stated173 countries; Dec. 8, 2020–Dec. 8, 2021

Why this verdict

The supplied abstract profile supports the first-year time horizon of 8 Dec 2020 to 8 Dec 2021. However, it does not provide the claimed country count of 173 countries, so that part of the claim is not verifiable at the supplied abstract depth.

1

Study evidence

Aggregate vaccine development and delivery costs during the first year were estimated at $79.4 billion.$79.4 billion

“Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation”
Claim 3 of 4SupportedEvery dollar spent on COVID-19 vaccine development and distribution generated an estimated $81 to $810 in economic value during the first year that vaccines were given.View evidenceHide evidence

As stated$81 to $810 per dollar spent

Why this verdict

The abstract-level profile supports that the study estimated first-year global vaccine benefits and compared them with development, manufacturing, and delivery costs. The stated $81–$810 per dollar corresponds to the reported $6.43–$64.3 trillion in benefits over $79.4 billion in costs, with rounding. The profile also reports a base-case ROI range of $59.7–$809 per dollar, so the story’s phrasing is best read as valued economic benefit per dollar spent rather than the exact ROI label.

1

Study evidence

Aggregate vaccine development and delivery costs during the first year were estimated at $79.4 billion.$79.4 billion

“Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation”
Claim 4 of 4SupportedThe study says COVID-19 vaccine development and delivery worldwide cost $79.4 billion, while the health and economic benefits were valued between $6.43 trillion and $64.3 trillion.View evidenceHide evidence

As stated$79.4 billion costs; $6.43 trillion to $64.3 trillion benefits

Why this verdict

The paper profile directly reports estimated aggregate costs of $79.4 billion and valued health/economic benefits of $6.43 trillion to $64.3 trillion for the first year of COVID-19 vaccination.

1

Study evidence

Aggregate vaccine development and delivery costs during the first year were estimated at $79.4 billion.$79.4 billion

“Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Probabilistic sensitivity analyses were conducted to assess parameter uncertainty in ROI estimates.

    The story reports estimate ranges but does not mention that the paper used probabilistic sensitivity analyses or that uncertainty analysis produced a distinct ROI range.

    From Probabilistic sensitivity analysis

  • A key limitation is that the analysis relied on previous analyses of COVID-19 vaccination impact rather than generating all impact estimates de novo.

    This limitation is listed in the paper profile but is not included among the story’s caveats.

    From model-based economic evaluation; stratified economic/model output analysis by income group; Probabilistic sensitivity an

5 things the story did carry across
  • The study was a model-based global economic evaluation of COVID-19 vaccination during 8 Dec 2020–8 Dec 2021, comparing valued benefits with vaccine development, manufacturing, and delivery costs.
  • The paper estimated total vaccine development/manufacturing/delivery costs at $79.4 billion and valued health/economic benefits at $6.43 trillion to $64.3 trillion.
  • The paper reported high estimated first-year returns on investment, including a base-case ROI range of $59.7 to $809 per dollar invested and PSA ROI ranges of $60.3 to $753.
  • The paper characterized distributional patterns by country income group: high-income countries had the largest health benefits per person vaccinated, while low-income countries had the largest nonhealth benefits per person vaccinated when expressed relative to GDP per capita.
  • A key limitation is that the analysis was limited to the first year of vaccination and did not include longer-term impacts beyond 8 Dec 2021.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in silico

1Lead resultin silicoEstimate the global return-on-investment (ROI) of COVID-19 vaccines during the first year of the vaccination programme by comparing modeled global health/economic benefits to costs of vaccine development, manufacturing, and delivery.model-based economic evaluationExpand

In plain English

Model-based global economic evaluation estimating life-years and QALYs averted by COVID-19 vaccination during 8 Dec 2020–8 Dec 2021, valuing health benefits using cost-benefit and cost-effectiveness approaches and comparing those benefits to vaccine development, manufacturing, and delivery costs to estimate global return-on-investment (ROI).

Key findings

  • Aggregate vaccine development and delivery costs during the first year were estimated at $79.4 billion.$79.4 billion
  • Health and economic benefits of vaccination were valued between $6.43 trillion and $64.3 trillion.$6.43–$64.3 trillion
“Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation”
What this piece can’t prove
  • Analysis relies on previous analyses of COVID-19 vaccination impact (secondary/aggregated inputs from prior work).
  • Time horizon limited to the first year of COVID-19 vaccination (8 Dec 2020–8 Dec 2021); longer-term impacts beyond that year were not included.
2in silicoCharacterize distributional patterns of benefits/ROI across country income groups (e.g., high-income vs low-income) using per-person and GDP-per-capita–scaled metrics.stratified economic/model output analysis by income groupExpand

In plain English

The study reports stratified model outputs comparing benefits/ROI of COVID-19 vaccination across country income groups. In abstract-level results, the authors state that high-income countries experienced the largest health benefits per person vaccinated, while low-income countries experienced the largest nonhealth benefits per person vaccinated when those nonhealth benefits were expressed as a proportion of GDP per capita. These comparisons were generated as part of the same economic model/evaluation and were presented using per-person and GDP-per-capita–scaled metrics.

Key findings

  • High-income countries saw the greatest health benefits per-person vaccinated, and low-income countries gained the greatest nonhealth benefits per-person vaccinated, when expressed as a proportion of gross domestic product per capita.
“High-income countries saw the greatest health benefits per-person vaccinated, and low-income countries gained the greatest nonhealth benefits per-person vaccinated, when expressed as a proportion of gross domestic product per capita.”
What this piece can’t prove
  • Time horizon of the analysis limited to the first year of vaccination (8 December 2020–8 December 2021), which may affect distributional interpretations.
  • Analysis relies on previous analyses of COVID-19 vaccination impact as inputs (as noted in abstract).

1 further detail could not be confirmed from the summary.

3in silicoQuantify uncertainty in ROI estimates via probabilistic sensitivity analyses (PSA) under both valuation approaches (cost-benefit and cost-effectiveness framing).Probabilistic sensitivity analysisExpand

In plain English

The abstract reports that probabilistic sensitivity analyses (PSA) were performed to quantify the impact of parameter uncertainty on estimated return-on-investment (ROI) for COVID-19 vaccination during the first year (8 Dec 2020–8 Dec 2021). Across PSA runs, ROIs ranged from $60.3 to $753 per dollar invested, reported as applying to both valuation approaches (cost-benefit and cost-effectiveness framing).

Key findings

  • Probabilistic sensitivity analyses were used to assess parameter uncertainty and produced ROI ranges of $60.3–$753 per dollar invested, reported for both cost-benefit and cost-effectiveness valuation approaches.$60.3–$753 per dollar invested (PSA range)
“Probabilistic sensitivity analyses were conducted to assess the impact of parameter uncertainty on ROI estimates.”
What this piece can’t prove
  • Analysis (including PSA) is limited to the first year of COVID-19 vaccination (8 Dec 2020–8 Dec 2021).
  • Study relies on previous analyses of COVID-19 vaccination impact (not all primary data generated de novo).
  • Abstract does not provide PSA methodological specifics (parameter distributions, sampling method, or number of simulations).
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation

PLOS Medicine · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation

PLOS Medicine · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.